The American Society of Nuclear Cardiology, together with eight other nuclear medicine and cardiology societies, have published a consensus document outlining the best practices for imaging and diagnosing cardiac amyloidosis.

The FDA announced Sept. 13 it identified low levels of N-nitrosodimethylamine, or NDMA, in popular heartburn drugs including Zantac.

Apple announced the initiation of three new large-scale medical studies, including one focused on women’s health, one focused on hearing and one focused on cardiovascular health and movement.

Contrary to a recent FDA advisory that acknowledged a late mortality signal with paclitaxel-coated and -eluting devices, a study published in the Journal of Endovascular Therapy found such stents safe in the long-term for treating femoropopliteal lesions in people with peripheral artery disease.

Men who struggle with erectile dysfunction—especially more severe cases—are at an increased risk of CHD, total heart disease, stroke and all-cause mortality, according to research published in the Journal of Sexual Medicine.

Discharging patients with suspected acute coronary syndrome (ACS) under a 0- and 1-hour high-sensitivity cardiac troponin T protocol is helpful for clearing waiting rooms, according to work presented at the ESC Congress Sept. 3.

Taking a nap once or twice a week—regardless of how long those naps are—can lower a person’s risk of incident heart disease, researchers report in the latest issue of BMJ Heart.

Researchers have successfully trained a convolutional neural network to detect congestive heart failure with 100% accuracy using data from just one heartbeat.

People who currently take or have recently taken fluoroquinolones face higher odds of aortic and mitral regurgitation, according to a report out of Canada.

Revolutions—dramatic and wide-reaching changes in the way something works, is organized or how we think about it—can sneak up on us.


CRF program planners describe how they’re building on last year’s momentum with even more practical programming.

Chicago biotech company BIOLIFE4D announced this week it had successfully 3D-bioprinted a mini human heart—something the company noted as a “significant milestone” on the path to printing full-sized hearts viable for transplant.